Cart
sales@molnova.com
Sofalcone
CAS No. 64506-49-6
Sofalcone( SU-88 )
Catalog No. M19821 CAS No. 64506-49-6
Sofalcone a gastric antiulcer agent in clinical use is known to induce the expression of Heme oxygenase-1 (HO-1) in gastric epithelium.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | 43 | In Stock |
|
| 200MG | 53 | In Stock |
|
| 500MG | 73 | In Stock |
|
| 1G | 105 | In Stock |
|
Biological Information
-
Product NameSofalcone
-
NoteResearch use only, not for human use.
-
Brief DescriptionSofalcone a gastric antiulcer agent in clinical use is known to induce the expression of Heme oxygenase-1 (HO-1) in gastric epithelium.
-
DescriptionSofalcone a gastric antiulcer agent in clinical use is known to induce the expression of Heme oxygenase-1 (HO-1) in gastric epithelium.(In Vitro):Sofalcone (50 μmol/L) significantly increases HO-1 mRNA expression compare with the control group in both trophoblasts and HUVECs (P<0.05 for both). Western blot analysis demonstrates that Sofalcone potently increases HO-1 protein expression in primary HUVECs treated for 24 hours. Western blot analysis also reveals a significant increase in the amount of Nrf2 in the nuclear fraction of HUVECs with Sofalcone treatment (50 μmol/L) for 6 hours. In primary HUVECs, expression of NQO1, TXN, and GCLC are increased in a dose dependently manner with Sofalcone treatment for 24 hours. Sofalcone significantly decreases the sFlt-1 concentrations in the culture media and dose dependently decreases the amount of THP-1 monocyte adherence to HUVECs.
-
In VitroSofalcone (50 μmol/L) significantly increases HO-1 mRNA expression compare with the control group in both trophoblasts and HUVECs (P<0.05 for both). Western blot analysis demonstrates that Sofalcone potently increases HO-1 protein expression in primary HUVECs treated for 24 hours. Western blot analysis also reveals a significant increase in the amount of Nrf2 in the nuclear fraction of HUVECs with Sofalcone treatment (50 μmol/L) for 6 hours. In primary HUVECs, expression of NQO1, TXN, and GCLC are increased in a dose dependently manner with Sofalcone treatment for 24 hours. Sofalcone significantly decreases the sFlt-1 concentrations in the culture media and dose dependently decreases the amount of THP-1 monocyte adherence to HUVECs.
-
In Vivo——
-
SynonymsSU-88
-
PathwayAutophagy
-
TargetAutophagy
-
RecptorHeme oxygenase-1
-
Research AreaInflammation/Immunology
-
Indicationgastroenteritis and ulcers
Chemical Information
-
CAS Number64506-49-6
-
Formula Weight450.52
-
Molecular FormulaC27H30O6
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESC\C(C)=C\COc1ccc(\C=C\C(=O)c2ccc(OC\C=C(\C)C)cc2OCC(O)=O)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Onda K et al. Sofalcone upregulates the nuclear factor (erythroid-derived 2)-like 2/heme oxygenase-1 pathway reduces soluble fms-like tyrosine kinase-1 and quenches endothelial dysfunction: potential therapeutic for preeclampsia. Hypertension. 2015 Apr;65(4):855-62.
molnova catalog
related products
-
ROC-325
ROC-325 (ROC 325, ROC325) is a novel, orally available inhibitor of lysosomal-mediated autophagy.
-
Oleandrin
Oleandrin, the principal cardiac glycoside component of PBI-524, can quantitatively account for regulation of BDNF at both the protein and transcriptional levels.
-
GSK4112
A potent and selective small molecule Rev-erbα agonist with EC50 of 0.4 uM in biochemical assay.
